72 reports

  • Vendor landscape
  • ASTRAZENECA

These agents are associated with reduced rates of hypoglycemia, moderate and continuous weight loss, and gastrointestinal side effects such as nausea and vomiting.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • 7.1 OVERVIEW

DESPITE ITS LOW COST, GASTROINTESTINAL (GI) SIDE EFFECTS ARE VERY COMMON WITH ACARBOSE, WHICH HAS PREVENTED ITS WIDESPREAD USE.

  • Type 2 Diabetes
  • Europe
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • Trial Results

GASTROINTESTINAL, AUTOIMMUNE DISEASE HISTORY OF MALIGNANCY, DRUG OR ALCOHOL ABUSE PARTICIPATION IN ANY PREVIOUS TRIAL ON ACE INHIBITOR TAKING OTHER INVESTIGATIONAL DRUGS WITHIN THE PAST ## DAYS KNOWN HISTORY OF SENSITIVITY / ALLERGY TO ACE INHIBITOR EXPECTED SURVIVAL LESS THAN ## YEARS

  • Type 2 Diabetes
  • World
  • Anthera Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Novartis AG

THE ENDOBARRIER GASTROINTESTINAL LINER IS TRANSORALLY PLACED IN THE GASTROINTESTINAL TRACT IN ORDER TO BYPASS A PORTION OF THE INTESTINE.

  • Type 2 Diabetes
  • United States
  • EnteroMedics Inc.
  • Novo Nordisk Group
  • VIVUS, Inc.

The combined portfolio of the two companies includes drugs in areas of dermatology, CNS, eye care, women' s health, urology, gastrointestinal, cystic fibrosis, cardiovascular, and infectious diseases.

  • Type 2 Diabetes
  • Actavis plc
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG

PATIENTS IN THE STANDARD CARE GROUP DEVELOPED CELLULITIS OF THE EFFECTED EXTREMITY (TWO PATIENTS), A GASTROINTESTINAL BLEED (ONE PATIENT), AND ACUTE PYELONEPHRITIS (ONE PATIENT).

  • Type 2 Diabetes
  • Japan
  • FirstString Research, Inc.
  • Organogenesis, Inc.
  • Smith & Nephew Plc

WE ARE ALSO ACTIVE IN THE INFECTION, NEUROSCIENCE AND GASTROINTESTINAL (ING) DISEASE AREAS.

  • Type 2 Diabetes
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.

WE ARE ALSO ACTIVE IN THE INFECTION, NEUROSCIENCE AND GASTROINTESTINAL (ING) DISEASE AREAS.

  • Type 2 Diabetes
  • United States
  • Amgen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH

GASTROINTESTINAL AND METABOLIC DISORDERS - DRUG PROFILE FGH-## - DRUG PROFILE KR-## - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description KR-## NA NA Korea Research Institute of Chemical Technology R& D Progress Resear

  • Diabetes
  • Type 2 Diabetes
  • World
  • Product Initiative
  • PhaseBio Pharmaceuticals, Inc.

GPR## is expressed at high concentrations in the pancreas and gastrointestinal tract.

  • Antimalarials
  • Molecular Diagnostic
  • Pharmaceutical
  • Type 2 Diabetes
  • Daiichi Sankyo Company
  • PIPELINE BY ELI LILLY AND COMPANY, H2 2017

Hanmi Pharma" s products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative
  • RDX-98940 - Drug Profile
  • Pipeline by Ardelyx Inc, H2 2017

The drug candidate is an agonist of TGR##, a G protein-coupled receptor found in the gastrointestinal (GI) tract.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative

Hyperglycemia - Pipeline Review, H## 2017 Reference Code: GMDHC##IDB Publication Date: June 2017 Introduction Global Markets Direct Report Coverage Global Markets Direct' s, ' Hyperglycemia - Pipeline Review, H## 2017', provides an overview of the Hyperglycemia pipeline landscape.

  • Pharmaceutical
  • Type 2 Diabetes
  • World
  • Product Initiative
  • Mitsubishi Corporation

GPR## is expressed at high concentrations in the pancreas and gastrointestinal tract.

  • Molecular Diagnostic
  • Pharmaceutical
  • Type 2 Diabetes
  • World
  • Product Initiative

Pharmaceuticals & Healthcare - Deals and Alliances Profile Poxel SA (POXEL) Report Code: GDPH##D Published: September 2017 Company Snapshot Company Overview Key Facts Poxel SA (Poxel) develops and markets drugs for metabolic diseases with concentration on type II diabetes.

  • Diabetes
  • Type 2 Diabetes
  • Japan
  • Company
  • POXEL SA
  • Jun 19, 2017: GI Dynamics Announces Additional Members to Its Scientific Advisory Board
  • Deal Sub Type

His clinical areas of expertise include laparoscopic and gastrointestinal surgery.

  • Healthcare
  • Type 2 Diabetes
  • United States
  • Company
  • GI Dynamics
  • Type 2 Diabetes Mellitus, Global, Pipeline Size by Therapy Area, 2016
  • Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 6)

Bile acid sequestrants such as Welchol (colesevelam) are a group of resins used to bind certain components of bile in the gastrointestinal tract.

  • Chronic Disease
  • Insulin
  • Pathology
  • Type 2 Diabetes
  • World
  • RDX-98940 - Drug Profile

It discovers, develops and commercializes small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • World
  • Product Initiative
  • JAN 21, 2016: VTV THERAPEUTICS INITIATES PHASE 2 TRIAL EVALUATING TTP273 FOR THE TREATMENT...
  • JAN 21, 2016: VTV THERAPEUTICS INITIATES PHASE 2 TRIAL EVALUATING TTP273 FOR THE TREATMENT...

In this study, all doses of TTP## were well tolerated with no serious adverse events or evidence of significant gastrointestinal side effects.

  • Type 2 Diabetes
  • United States
  • Company Financials
  • Company Operations
  • vTv Therapeutics LLC

The company' s products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others.

  • Cholesterol
  • Type 2 Diabetes
  • South Korea
  • United States
  • World
  • BARDOXOLONE METHYL - DRUG PROFILE

Gastrointestinal events were the frequent adverse event leading to withdrawal during XP## treatment.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • RPI

Report covers products from therapy areas Metabolic Disorders, Undisclosed and Gastrointestinal which include indications Diabetes, Type ## Diabetes, Unspecified, Non Alcoholic Fatty Liver Disease (NAFLD) and Non- Alcoholic Steatohepatitis (NASH).

  • Molecular Diagnostic
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • GlaxoSmithKline plc
  • May 04, 2017: Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation...

The most common side effects were mild gastrointestinal issues, which were comparable between the ZGN-## and placebo groups, headache and procedural related irritation.

  • Type 2 Diabetes
  • United States
  • World
  • Product Initiative
  • Zafgen, Inc.
  • Active Wound Dressing
  • Clinical Trial
  • Type 2 Diabetes
  • Wound Dressing
  • GlobalData's company
  • SINOGLIATIN - DRUG PROFILE

In addition to the high efficacy, the results showed an excellent tolerability and safety profile with low risk of hypoglycemia or other side effects (such as gastrointestinal discomfort) common in many diabetes treatments.

  • Endocrine Disease
  • Type 2 Diabetes
  • China
  • Product Initiative
  • Hua Medicine

In addition to the high efficacy, the results showed an excellent tolerability and safety profile with low risk of hypoglycemia or other side effects (such as gastrointestinal discomfort) common in many diabetes treatments.

  • Diabetes
  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • PRODUCTS UNDER INVESTIGATION BY UNIVERSITIES/INSTITUTES, H2 2016
  • PRODUCTS UNDER INVESTIGATION BY UNIVERSITIES/INSTITUTES, H2 2016 (CONTD..3)

It discovers, develops and commercializes medicines for gastrointestinal disorders.

  • Biotechnology
  • Type 2 Diabetes
  • Company
  • Product Initiative
  • AstraZeneca PLC
  • Apr 02, 2016: Semaglutide demonstrated superior improvements in glycaemic control vs placebo...
  • Apr 02, 2016: Semaglutide demonstrated superior improvements in glycaemic control vs placebo...

Similarly, in SUSTAIN ##, the most common adverse events observed for adults treated with ##. ## mg semaglutide and exenatide ER were also gastrointestinal (##. ##% and ##. ##%).

  • Insulin
  • Type 2 Diabetes
  • United States
  • Company
  • Novo Nordisk Group
  • CHRONIC KIDNEY DISEASE (CHRONIC RENAL FAILURE) - PIPELINE BY GNI GROUP LTD
  • CHRONIC KIDNEY DISEASE (CHRONIC RENAL FAILURE) - PIPELINE BY LUPIN LTD

Patiromer is not absorbed and acts within the gastrointestinal tract.

  • Genitourinary System Disease
  • Pharmaceutical
  • Prosthesis
  • Type 2 Diabetes
  • Angion Biomedica Corp.

Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Ophthalmology, Cardiovascular, Central Nervous System, Genetic Disorders and Respiratory which include indications Fibrosis, Kidn

  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • Sirnaomics, Inc.